STALEVO 100 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Stalevo 100, and when can generic versions of Stalevo 100 launch?
Stalevo 100 is a drug marketed by Orion Pharma and is included in one NDA.
The generic ingredient in STALEVO 100 is carbidopa; entacapone; levodopa. There are eighteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the carbidopa; entacapone; levodopa profile page.
Summary for STALEVO 100

Recent Clinical Trials for STALEVO 100
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 4 |
Asan Medical Center | N/A |
SynAgile Corporation | Phase 2 |
Pharmacology for STALEVO 100
Drug Class | Aromatic Amino Acid Catechol-O-Methyltransferase Inhibitor |
Mechanism of Action | Catechol O-Methyltransferase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for STALEVO 100
US Patents and Regulatory Information for STALEVO 100
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Orion Pharma | STALEVO 100 | carbidopa; entacapone; levodopa | TABLET;ORAL | 021485-002 | Jun 11, 2003 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for STALEVO 100
International Patents for STALEVO 100
See the table below for patents covering STALEVO 100 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Iceland | 3290 | See Plans and Pricing | |
Poland | 152642 | See Plans and Pricing | |
Japan | 4204783 | See Plans and Pricing | |
Czechoslovakia | 8808440 | See Plans and Pricing | |
Japan | S63170311 | MEDICINAL COMPOSITION CONTAINING CATECHOL DERIVATIVE AS EFFECTIVE COMPONENT | See Plans and Pricing |
European Patent Office | 1189608 | PREPARATION PHARMACEUTIQUE A BASE DE LEVODOPA/CARBIDOPA/ENTACAPONE (LEVODOPA/CARBIDOPA/ENTACAPONE PHARMACEUTICAL PREPARATION) | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for STALEVO 100
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0426468 | C00426468/01 | Switzerland | See Plans and Pricing | FORMER REPRESENTATIVE: BOHEST AG, CH |
0426468 | CA 2004 00007 | Denmark | See Plans and Pricing | |
0426468 | 0490007-2 | Sweden | See Plans and Pricing | PRODUCT NAME: (E)-2-CYANO-N,N-DIETYL-3-(3,4-DIHYDROXI-5-NITROFENYL)AKRYLAMID; REGSISTRATION NO/DATE: EU/1/03/260/001 20031017 |
0426468 | 91071 | Luxembourg | See Plans and Pricing | 91071, EXPIRES: 20151101 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |